Related Experiment Video
Updated: May 24, 2025

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions
Published on: June 11, 2015
Inhibition of IP3 (Inositol 1,4,5-Trisphosphate) Receptors Retards SARS-CoV-2-Induced Endothelial von Willebrand
Xin-Yi Yu1, Xin-Yu Jia1, Ting-Yu Wang1
1The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China.
Insights
Cytoskeleton-associated protein 4 (CKAP4) mediates COVID-19 coagulopathy by triggering calcium release from the endoplasmic reticulum, leading to increased von Willebrand factor secretion and thrombosis. Targeting IP3 receptors may prevent these effects.
Area of Science:
- Biomedical research
- Molecular biology
- Pathophysiology
Background:
- COVID-19 patients exhibit hypercoagulability and thrombosis.
- Cytoskeleton-associated protein 4 (CKAP4) is a receptor for SARS-CoV-2 spike protein and linked to COVID-19 coagulopathy.
- The precise mechanism of CKAP4-mediated thrombosis remains unclear.
Purpose of the Study:
- To investigate the signaling pathways linking spike protein-CKAP4 interaction to von Willebrand factor (vWF) secretion and thrombosis.
- To identify potential therapeutic targets for COVID-19-associated coagulopathy.
Main Methods:
- Treatment of endothelial cells (ECs) with SARS-CoV-2 spike protein.
- Use of calcium chelators (BAPTA-AM), calcium channel blockers, and inositol 1,4,5-trisphosphate (IP3) receptor inhibitors.
- Knockdown of IP3 receptor 1 (IP3R1).
- Administration of KT-362, an IP3R-targeting drug.
- In vivo studies in mice with endothelial-specific CKAP4 overexpression.
Main Results:
- Spike protein induced vWF secretion, FVIII-vWF binding, and platelet adhesion in ECs, effects blocked by BAPTA-AM.
- Calcium release from the endoplasmic reticulum (ER) via IP3 receptors (IP3Rs) was critical for these responses.
- Inhibition of IP3Rs, particularly IP3R1, reversed spike protein-induced vWF secretion and procoagulant state.
- KT-362 repressed spike protein-induced vWF secretion in vitro and in vivo.
- IP3Rs activation promoted vWF secretion independently of CKAP4.
Conclusions:
- IP3Rs-mediated calcium release from the ER is a key mechanism in spike protein-induced vWF secretion and thrombosis.
- Targeting IP3Rs represents a potential therapeutic strategy for managing COVID-19-associated coagulopathy.
Abstract:
Patients with coronavirus disease 2019 (COVID-19) are at high risk of developing a hypercoagulable state and thrombosis. The von Willebrand factor (vWF) produced by endothelial cells (ECs) is a critical thrombosis regulator. We previously found that cytoskeleton-associated protein 4 (CKAP4) is a novel receptor for the spike protein of severe acute respiratory syndrome coronavirus-2 and is involved in COVID-19-associated coagulopathy. However, the underlying mechanism involved remains unclear. This study aimed to explore the signaling pathways involved in spike protein-CKAP4-induced vWF secretion and thrombosis. Treatment of ECs with the spike protein significantly induced vWF secretion, coagulation factor VIII (FVIII)-vWF binding, and platelet adhesion to ECs, which were blocked by the selective intracellular calcium chelator, BAPTA-AM. Furthermore, using several calcium channel-blocking drugs and small-molecule inhibitors, we found that calcium released from the endoplasmic reticulum (ER) is involved in this process. IP3 (inositol 1,4,5-trisphosphate) receptors (IP3Rs) inhibition ameliorated spike protein-induced vWF secretion, FVIII-vWF binding affinity, and platelet adhesion to ECs. Specifically, the knockdown of IP3R1, a crucial type of IP3Rs, reversed spike protein-induced endothelial vWF secretion, and the procoagulant state. Moreover, KT-362, an investigational and clinically relevant antihypertensive drug targeting IP3Rs-mediated calcium release, repressed spike protein-induced endothelial vWF secretion. Conversely, the IP3Rs agonist promoted endothelial vWF secretion, which was not affected by CKAP4 knockdown. In vivo treatment of endothelial-specific human CKAP4 overexpression mice with KT-362 retarded spike protein-induced vWF secretion and thrombosis. Thus, IP3Rs mediated calcium release from the ER and contributed to spike protein-induced vWF secretion and thrombosis, making them potential therapeutic targets for COVID-19-associated coagulopathy.
Related Concept Videos
IP3/DAG Signaling Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
GPCRs Regulate Adenylyl Cylase Activity
The JAK-STAT Signaling Pathway

